What is a stock summary page? Click here for an overview.
Business Description
CSPC Pharmaceutical Group Ltd
ISIN : HK1093012172
Description
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 27.75 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | 151 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.94 | |||||
Beneish M-Score | -1.91 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.4 | |||||
3-Year EBITDA Growth Rate | 3.2 | |||||
3-Year EPS without NRI Growth Rate | 3.6 | |||||
3-Year FCF Growth Rate | -25.6 | |||||
3-Year Book Growth Rate | 11.5 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 99.97 | |||||
9-Day RSI | 97.88 | |||||
14-Day RSI | 85.73 | |||||
3-1 Month Momentum % | -8.57 | |||||
6-1 Month Momentum % | -12.67 | |||||
12-1 Month Momentum % | -32.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.54 | |||||
Quick Ratio | 2.22 | |||||
Cash Ratio | 1.03 | |||||
Days Inventory | 125.04 | |||||
Days Sales Outstanding | 70.76 | |||||
Days Payable | 114.44 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 6.84 | |||||
Dividend Payout Ratio | 0.3 | |||||
3-Year Dividend Growth Rate | 12.8 | |||||
Forward Dividend Yield % | 7.32 | |||||
5-Year Yield-on-Cost % | 22.78 | |||||
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | 6.3 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 70.59 | |||||
Operating Margin % | 21.09 | |||||
Net Margin % | 17.02 | |||||
FCF Margin % | 7.58 | |||||
ROE % | 15.49 | |||||
ROA % | 11.22 | |||||
ROIC % | 20.68 | |||||
3-Year ROIIC % | 13.31 | |||||
ROC (Joel Greenblatt) % | 54.09 | |||||
ROCE % | 18.21 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 9.37 | |||||
Forward PE Ratio | 9.21 | |||||
PE Ratio without NRI | 9.37 | |||||
Shiller PE Ratio | 8.03 | |||||
Price-to-Owner-Earnings | 17.65 | |||||
PEG Ratio | 0.66 | |||||
PS Ratio | 1.75 | |||||
PB Ratio | 1.52 | |||||
Price-to-Tangible-Book | 1.65 | |||||
Price-to-Free-Cash-Flow | 23.09 | |||||
Price-to-Operating-Cash-Flow | 12.65 | |||||
EV-to-EBIT | 6.24 | |||||
EV-to-Forward-EBIT | 7.23 | |||||
EV-to-EBITDA | 6.24 | |||||
EV-to-Forward-EBITDA | 7.32 | |||||
EV-to-Revenue | 1.35 | |||||
EV-to-Forward-Revenue | 1.29 | |||||
EV-to-FCF | 17.75 | |||||
Price-to-GF-Value | 0.68 | |||||
Price-to-Projected-FCF | 0.74 | |||||
Price-to-DCF (Earnings Based) | 0.3 | |||||
Price-to-DCF (FCF Based) | 0.67 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.64 | |||||
Price-to-Graham-Number | 0.81 | |||||
Price-to-Net-Current-Asset-Value | 4.01 | |||||
Earnings Yield (Greenblatt) % | 16.03 | |||||
FCF Yield % | 4.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CHJTF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CSPC Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 4,220.83 | ||
EPS (TTM) ($) | 0.06 | ||
Beta | 0.32 | ||
3-Year Sharpe Ratio | -0.68 | ||
3-Year Sortino Ratio | -0.93 | ||
Volatility % | 53.37 | ||
14-Day RSI | 85.73 | ||
14-Day ATR ($) | 0.001773 | ||
20-Day SMA ($) | 0.54195 | ||
12-1 Month Momentum % | -32.81 | ||
52-Week Range ($) | 0.5409 - 0.96 | ||
Shares Outstanding (Mil) | 11,443.7 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
CSPC Pharmaceutical Group Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
CSPC Pharmaceutical Group Ltd Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
CSPC Pharmaceutical Group Ltd Frequently Asked Questions
What is CSPC Pharmaceutical Group Ltd(CHJTF)'s stock price today?
The current price of CHJTF is $0.56. The 52 week high of CHJTF is $0.96 and 52 week low is $0.54.
When is next earnings date of CSPC Pharmaceutical Group Ltd(CHJTF)?
The next earnings date of CSPC Pharmaceutical Group Ltd(CHJTF) is 2025-03-28 Est..
Does CSPC Pharmaceutical Group Ltd(CHJTF) pay dividends? If so, how much?
The Dividend Yield %  of CSPC Pharmaceutical Group Ltd(CHJTF) is 6.84% (As of Today), Highest Dividend Payout Ratio of CSPC Pharmaceutical Group Ltd(CHJTF) was 0.47. The lowest was 0.25. And the median was 0.32. The  Forward Dividend Yield % of CSPC Pharmaceutical Group Ltd(CHJTF) is 7.32%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |